NL-OMON25401招募中不适用
A phase II study of sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) non-small lung cancer (NSCLC) with a K-Ras mutation.
Vrije Universiteit Medisch centrumPostbus 70571007 MB AmsterdamNetherlands0 个研究点目标入组 46 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 46
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically advanced NSCLC stage IIIB or IV harbouring a K-RAS mutation;
- •2. Disease progression after at least 1 prior chemotherapy regimen that should include a platinum doublet;
排除标准
- •Excluded medical conditions:
- •1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arythmias requiring anti-arythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension;
研究者
相似试验
已完成
2 期
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002972Kyorin University Hospital80
已完成
2 期
A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC (STAGE IIIB OR IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH A K-RAS MUTATIO10038666non-small cell lung cancerNL-OMON32472Vrije Universiteit Medisch Centrum48
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
招募中
2 期
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
已完成
2 期
Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000007199Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University25